Market Snapshot – Yunnan Baiyao (000538.SZ)
- Opening price: CN H 52.49
- Volume (last 24 h): CN H 495.8 million
- Shares outstanding: 1.8 billion
- Market capitalisation: CN H 13 billion
- 24‑hour change: 0 % (flat)
- Trading session ending: 09:08 AM Central Europe, Friday 23 Oct 2026
- Price relative to 200‑day SMA: CN H 50.39 (above the moving average)
- 52‑week range: CN H 58.2 (high) – CN H 46.29 (low)
Since the close of the month, the share price has appreciated by 2.67 %, signalling a steady, albeit cautious, market sentiment. The trading volume indicates moderate liquidity, with roughly one‑third of the outstanding shares being traded each day.
Peer Performance (last 24 h)
| Stock | Symbol | 24‑hour change | Current price | Market cap | P/E ratio |
|---|---|---|---|---|---|
| Accelink | 002281.SZ | 0 % | CN H 126.45 | CN H 15.5 bn | 92.58 |
| Xinyi Solar | 0968.HK | –0.82 % | HKD 1.82 | HKD 16.8 bn | 103.33 |
| Guangxi Yuegui Guangye Hol | 000833.SZ | 0 % | CNY 17.48 | CNY 14.3 bn | 15.26 |
| Jiangsu Hengli Hydraulic C | 601100.SS | 0 % | CN H 89.72 | CN H 15.6 bn | 41.23 |
| Kaishan | 300257.SZ | 0 % | CNY 14.22 | CNY 14.3 bn | 37.86 |
The lack of movement across several peer names underlines a broader market consolidation. While Yunnan Baiyao trades at a modest valuation relative to its peers, its stable performance and strong liquidity position it favourably for long‑term investors.
Company Overview
Yunnan Baiyao Group Co. Ltd. is a diversified healthcare player headquartered in Kunming, China, and listed on the Shenzhen Stock Exchange. Founded on 6 November 1993, the firm manufactures a broad portfolio that includes:
- Chemical raw medicines and preparations
- Proprietary Chinese medicines
- Chinese herbal medicines
- Medical equipment
The company’s integrated R&D and manufacturing capabilities have allowed it to maintain a competitive edge in both domestic and international markets. Further details can be found on the corporate website: www.yunnanbaiyao.com.cn .
Forward‑Looking Outlook
Yunnan Baiyao’s current positioning—above its 200‑day moving average, steady volume, and a healthy market cap—suggests a resilient foundation. As the company continues to innovate within the pharmaceutical and medical device sectors, it is poised to capture incremental gains in a market that increasingly values quality and compliance. Investors should monitor upcoming earnings releases and regulatory developments, which may provide further catalysts for price appreciation.
